Association of Pediatric Vasculitis Activity Score with immunoglobulin A vasculitis with nephritis.
Children
Immunoglobulin A vasculitis
Immunoglobulin A vasculitis with nephritis
Pediatric Vasculitis Activity Score
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
20
03
2022
accepted:
27
06
2022
revised:
23
06
2022
pubmed:
28
7
2022
medline:
19
1
2023
entrez:
27
7
2022
Statut:
ppublish
Résumé
Immunoglobulin A vasculitis with nephritis (IgAVN) is the most serious complication affecting long-term prognosis. Understanding the risk factors and markers for the development of IgAVN is essential. The aim of this study is to identify IgAVN-associated factors and to evaluate the usability of Pediatric Vasculitis Activity Score (PVAS) at diagnosis as an early marker for the development of IgAVN. We conducted a retrospective case-control study of 314 patients divided into two groups: those with nephritis (IgAVN) and without nephritis (non-IgAVN). The groups were compared in terms of clinical symptoms, laboratory values, and PVAS values. In total, 18.5% of the patients had IgAVN; they were older than the non-IgAVN patients (median age was 8.8, p < 0.05). Arthritis/arthralgia, abdominal pain, and intestinal bleeding were more common, systolic and diastolic BP were higher in IgAVN (p < 0.05). CRP, serum creatinine, and urine protein/Cr, PVAS were higher, while serum albumin was lower in IgAVN (p < 0.05). The receiver operator characteristic curve (ROC) analysis showed that IgAV patients with a determined cut-off PVAS value greater than 3 had 70.7% sensitivity in predicting whether or not they would develop IgAVN. Logistic regression analysis found that PVAS > 3 and low serum albumin at the time of diagnosis were independent risk factors for IgAVN. Our study revealed that PVAS > 3 at diagnosis is an independent predictor of IgAVN. Patients with PVAS > 3 should be followed more closely to ensure early diagnosis and management of IgAVN. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
Immunoglobulin A vasculitis with nephritis (IgAVN) is the most serious complication affecting long-term prognosis. Understanding the risk factors and markers for the development of IgAVN is essential. The aim of this study is to identify IgAVN-associated factors and to evaluate the usability of Pediatric Vasculitis Activity Score (PVAS) at diagnosis as an early marker for the development of IgAVN.
METHODS
We conducted a retrospective case-control study of 314 patients divided into two groups: those with nephritis (IgAVN) and without nephritis (non-IgAVN). The groups were compared in terms of clinical symptoms, laboratory values, and PVAS values.
RESULTS
In total, 18.5% of the patients had IgAVN; they were older than the non-IgAVN patients (median age was 8.8, p < 0.05). Arthritis/arthralgia, abdominal pain, and intestinal bleeding were more common, systolic and diastolic BP were higher in IgAVN (p < 0.05). CRP, serum creatinine, and urine protein/Cr, PVAS were higher, while serum albumin was lower in IgAVN (p < 0.05). The receiver operator characteristic curve (ROC) analysis showed that IgAV patients with a determined cut-off PVAS value greater than 3 had 70.7% sensitivity in predicting whether or not they would develop IgAVN. Logistic regression analysis found that PVAS > 3 and low serum albumin at the time of diagnosis were independent risk factors for IgAVN.
CONCLUSION
Our study revealed that PVAS > 3 at diagnosis is an independent predictor of IgAVN. Patients with PVAS > 3 should be followed more closely to ensure early diagnosis and management of IgAVN. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 35895124
doi: 10.1007/s00467-022-05675-2
pii: 10.1007/s00467-022-05675-2
doi:
Substances chimiques
Immunoglobulin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
763-770Informations de copyright
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Piram M, Mahr A (2013) Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. Curr Opin Rheumatol 25:171–178. https://doi.org/10.1097/BOR.0b013e32835d8e2a
doi: 10.1097/BOR.0b013e32835d8e2a
Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P (2006) EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 65:936–941. https://doi.org/10.1136/ard.2005.046300
doi: 10.1136/ard.2005.046300
Chan H, Tang YL, Lv XH, Zhang GF, Wang M, Yang HP, Li Q (2016) Risk factors associated with renal involvement in childhood Henoch-Schönlein purpura: a meta-analysis. PLoS One 30:e0167346. https://doi.org/10.1371/journal.pone.0167346
Scott K, Why V, Avner ED (2016) Henoch-Schönlein purpura nephritis. In: RM Kliegman, BF Stanton, JW St. Geme, NF Schor, RE Behrman (eds) Nelson Texbook of Pediatrics, 20th edn. Philadelphia. pp 2505
Butani L, Morgenstern BZ (2007) Long-term outcome in children after Henoch-Schonlein purpura nephritis. Clin Pediatr (Phila) 46:505–511. https://doi.org/10.1177/0009922806298896
doi: 10.1177/0009922806298896
Sun L, Xie B, Zhang Q, Wang Y, Wang X, Gao B, Liu M, Wang M (2017) Biomarkers identification by a combined clinical and metabonomics analysis in Henoch-Schonlein purpura nephritis children. Oncotarget 8:114239–114250. https://doi.org/10.18632/oncotarget.23207
doi: 10.18632/oncotarget.23207
Fang X, Wu H, Lu M, Cao Y, Wang R, Wang M, Gao C, Xia Z (2020) Urinary proteomics of Henoch-Schönlein purpura nephritis in children using liquid chromatography-tandem mass spectrometry. Clin Proteomics 17:10. https://doi.org/10.1186/s12014-020-09274-x
doi: 10.1186/s12014-020-09274-x
Fuentes Y, Hernández AM, García-Roca P, Valverde S, Velásquez-Jones LF, Sosa G, Duarte-Durán UO, Ortíz L, Maldonado R, Faugier E, Ramón-García G, Medeiros M (2014) Urinary MCP-1/creatinine in Henoch-Schönlein purpura and its relationship with nephritis. Pediatr Nephrol 29:1047–1052. https://doi.org/10.1007/s00467-013-2740-0
doi: 10.1007/s00467-013-2740-0
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68:1827–1832. https://doi.org/10.1136/ard.2008.101279
doi: 10.1136/ard.2008.101279
Dolezalova P, Price-Kuehne FE, Özen S, Benseler SM, Cabral DA, Anton J, Brunner J, Cimaz R, O’Neil KM, Wallace CA, Wilkinson N, Eleftheriou D, Demirkaya E, Böhm M, Krol P, Luqmani RA, Brogan PA (2013) Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 72:1628–1633. https://doi.org/10.1136/annrheumdis-2012-202111
doi: 10.1136/annrheumdis-2012-202111
Morishita KA, Moorthy LN, Lubieniecka JM, Twilt M, Yeung RSM, Toth MB, Shenoi S, Ristic G, Nielsen SM, Luqmani RA, Li SC, Lee T, Lawson EF, Kostik MM, Klein-Gitelman M, Huber AM, Hersh AO, Foell D, Elder ME, Eberhard BA, Dancey P, Charuvanij S, Benseler SM, Cabral DA, ARChiVe Investigators Network within the PedVas Initiative (2017) Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 69:1470–1479. https://doi.org/10.1002/art.40112
doi: 10.1002/art.40112
Eleftheriou D, Varnier G, Dolezalova P, McMahon AM, Al-Obaidi M, Brogan PA (2015) Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom. Arthritis Res Ther 17:36. https://doi.org/10.1186/s13075-015-0545-1
doi: 10.1186/s13075-015-0545-1
Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69:798–806. https://doi.org/10.1136/ard.2009.116657
doi: 10.1136/ard.2009.116657
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, Subcommittee on Screening and Management of High Blood Pressure in Children (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904, 142:e20181739. https://doi.org/10.1542/peds.2018-1739
Watt G, Omar F, Brink A, McCulloch M (2016) Laboratory investigation of the child with suspected renal disease. In: Avner ED, Harmon WE, Nıaduet P, Yoshikawa N, Emma F, Goldstein SL (eds). Pediatr Nephrol, 7th edn. Heidelberg, Berlin, pp 614–633
Edström Halling S, Söderberg MP, Berg UB (2010) Predictors of outcome in Henoch-Schönlein nephritis. Pediatr Nephrol 25:1101–1108. https://doi.org/10.1007/s00467-010-1444-y
doi: 10.1007/s00467-010-1444-y
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138
Yap K, Lau PYW (2016) Hematuria and proteinuria. In: Geary DF, Schaefer F (eds). Pediatr Kidney Dis, 2nd edn. Berlin, pp 391–418
Nakanishi K, Yoshikawa N (2016) Immunoglobulin A nephropaties in children ( includes HSP). In: Avner ED, Harmon WE, Nıaduet P, Yoshikawa N, Emma F, Goldstein SL (eds) Pediatr Nephrol, 7th edn. Heidelberg, Berlin pp 1001–1002
Bogdanović R (2009) Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr 98:1882–1889. https://doi.org/10.1111/j.1651-2227.2009.01445.x
doi: 10.1111/j.1651-2227.2009.01445.x
Liu C, Luo L, Fu M, Li Z, Liu J (2022) Analysis of children with Henoch-Schonlein purpura secondary to infection. Clin Rheumatol 41:803–810. https://doi.org/10.1007/s10067-021-06007-9
doi: 10.1007/s10067-021-06007-9
Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, Locatelli F, Cagnoli L (2006) Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis 47:993–1003. https://doi.org/10.1053/j.ajkd.2006.02.178
doi: 10.1053/j.ajkd.2006.02.178
Buscatti IM, Casella BB, Aikawa NE, Watanabe A, Farhat SCL, Campos LMA, Silva CA (2018) Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center. Clin Rheumatol 37:1319–1324. https://doi.org/10.1007/s10067-017-3972-3
doi: 10.1007/s10067-017-3972-3
Huang X, Wu X, Le W, Hao Y, Wu J, Zeng C, Liu Z, Tang Z (2018) Renal prognosis and related risk factors for Henoch-Schönlein purpura nephritis: a Chinese adult patient cohort. Sci Rep 8:5585. https://doi.org/10.1038/s41598-018-23638-2
doi: 10.1038/s41598-018-23638-2
Lu S, Liu D, Xiao J, Cheng G, Wang X, Zhang X, Yuan W, Dou Y, Liu Z, Zhao Z (2016) Independent association between hyperuricemia and histopathological parameters in Chinese patients with Henöch-Schönlein purpura nephritis. Clin Lab 62:2271–2275. https://doi.org/10.7754/Clin.Lab.2016.160303
doi: 10.7754/Clin.Lab.2016.160303
Zheng X, Chen Q, Chen L (2019) Obesity is associated with Henoch-Schönlein Purpura Nephritis and development of end-stage renal disease in children. Ren Fail 41:1016–1020. https://doi.org/10.1080/0886022X.2019.1685545
doi: 10.1080/0886022X.2019.1685545
Batu ED, Ozen S (2020) Measuring vasculitis with numbers: outcome scores. Curr Rheumatol Rev 16:21–28. https://doi.org/10.2174/1573397115666191126093927
doi: 10.2174/1573397115666191126093927
Demirkaya E, Ozen S, Pistorio A, Galasso R, Ravelli A, Hasija R, Baskin E, Dressler F, Fischbach M, Garcìa Consuegra J, Iagaru N, Pasic S, Scarpato S, van Rossum MA, Apaz MT, Barash J, Calcagno G, Gonzalez B, Hoppenreijs E, Ioseliani M, Mazur-Zielinska H, Vougiouka O, Wulffraat N, Luqmani R, Martini A, Ruperto N, Dolezalova P, Paediatric Rheumatology International Trials Organization (PRINTO) (2012) Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clin Exp Rheumatol 30(1 Suppl 70):162–168
Tekgöz N, Aydın F, Kurt T, Sezer M, Tekin Z, Karagöl C, Çakar N, Acar B (2021) Clinical features and outcomes of childhood polyarteritis nodosa: a single referral center experience. Mod Rheumatol 31:1142–1147. https://doi.org/10.1080/14397595.2021.1886892
doi: 10.1080/14397595.2021.1886892